Marketing-authorisation holder
Novartis Gene Therapies, Inc.
3 medicines in 2 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
3 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ITVISMA4x10^13VG/ML · Injection | Onasemnogene abeparvovec | United States | Marketed | 2025 |
| Zolgensma2x10^13VG/ML · Injection | Onasemnogene abeparvovec | United States | Marketed | 2019 |
| Zolgensma | Onasemnogene abeparvovec | Saudi Arabia | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 2 | 2 | 0 | CompaniesAll medicines |
| Saudi Arabia | 1 | 1 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.